Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co.

Meyer Handelman Co. reduced its position in Amgen Inc. (NASDAQ:AMGN) by 4.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 119,231 shares of the medical research company’s stock after selling 5,682 shares during the quarter. Amgen comprises about 1.2% of Meyer Handelman Co.’s holdings, making the stock its 25th largest position. Meyer Handelman Co.’s holdings in Amgen were worth $39,025,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the fourth quarter valued at about $26,000. Howard Hughes Medical Institute purchased a new position in Amgen during the second quarter worth about $32,000. Olistico Wealth LLC acquired a new stake in Amgen in the fourth quarter valued at about $33,000. Cloud Capital Management LLC acquired a new stake in Amgen in the third quarter valued at about $34,000. Finally, Saranac Partners Ltd purchased a new stake in Amgen in the 3rd quarter valued at approximately $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $351.85 on Wednesday. The business’s 50 day simple moving average is $363.37 and its 200-day simple moving average is $331.58. The firm has a market capitalization of $189.67 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 3.46 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period last year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive cardiovascular data for Amgen’s Repatha: a trial showed a 31% reduction in first major cardiovascular events in a high‑risk population without known significant atherosclerosis — a tailwind for Repatha’s commercial outlook and long‑term revenue potential. Amgen: Repatha Cuts Risk…
• Positive Sentiment: High‑profile media/analyst praise has supported sentiment — Jim Cramer noted Amgen as an attractive large‑cap biotech holding, and Zacks highlighted Amgen’s resilient drug portfolio as offsetting industry headwinds. Those endorsements can boost short‑term demand. Amgen (AMGN) Stock Up Since Jim Cramer Said…
• Positive Sentiment: Zacks analyst commentary reiterates AMGN’s upside from a diversified drug portfolio and steady cash flows, supporting the stock amid sector volatility. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Neutral Sentiment: Sector news (other biotech trial readouts and IPO activity) is driving broader health‑care flows but is not specific to Amgen’s fundamentals; watch market‑wide risk appetite. Viridian tumbles on positive data for key eye drug prospect
• Negative Sentiment: FDA safety warning on Tavneos (Amgen’s drug for certain rare autoimmune diseases): regulators identified dozens of drug‑induced liver injury cases (reports cite ~76 cases) and urged close monitoring and prompt discontinuation if liver damage is suspected — a material safety/regulatory overhang that could affect prescribing, labeling, and long‑term sales. US FDA warns of liver injury cases tied to Amgen’s rare disease drug
• Negative Sentiment: Competitive pressure: Teva’s FDA approval of a Prolia (denosumab) biosimilar and other biosimilar filings increase competition in bone‑health markets, which could weigh on Amgen’s Prolia pricing and market share over time. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Wall Street Analyst Weigh In

Several equities analysts have issued reports on AMGN shares. Wells Fargo & Company boosted their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Royal Bank Of Canada lifted their price target on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. Cantor Fitzgerald upped their price objective on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Morgan Stanley increased their price objective on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. Finally, Citigroup raised their target price on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.